TIM-3 expression by regulatory lymphocytes (CD4+) is correlated with disease progression in NSCLC, ovarian cancer (OC), prostate cancer (PC), and other types of cancer [3]. Here, HAVCR2 is linked to non-small cell lung carcinoma.